|Test||MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (2A, 2B, FMTC), MUTATION SCREEN, BLOOD|
|Methodology||DNA sequencing of exons 10,11,13,14,15, and 16 of the RET proto-oncogene|
|Description||Useful for confirmation of diagnosis of MEN 2A, 2B and FMTC and for documentation of germline mutation to distinguish familial MTC from sporadic MTC.
NOTE: This test, when ordered on Medicare patients, is subject to the Local Coverage Determination (LCD) policy "Molecular Diagnostics". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The carrier web site, CMS web site or the NorDx Limited Coverage Documentation Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen.
|Specimen||All specimens should include a "Molecular Genetics Congenital Disorders Request Form" (Supply T245) with information including relevant clinical and family information. This form is supplied by NorDx. Specimens must arrive within 96 hours of draw.
|Reference Values||An interpretive report will be issued.|
|Analytic Time||4 Days|
|Day(s) Test Set Up||Wednesday|